Amgen has been granted a patent for bispecific antigen binding proteins that target human CGRP and PAC1 receptors, potentially treating conditions like chronic pain, migraine, and cluster headaches. The patent includes specific sequences for the antibody components. GlobalData’s report on Amgen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Amgen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Amgen, NSAID cancer drugs was a key innovation area identified from patents. Amgen's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Bispecific antibody for human cgrp and pac1 receptors

Source: United States Patent and Trademark Office (USPTO). Credit: Amgen Inc

A recently granted patent (Publication Number: US11919964B2) discloses a bispecific heterodimeric antibody designed to target the human CGRP receptor and the amino-terminal extracellular domain of the human PAC1 receptor. The antibody comprises specific sequences for the light and heavy chains from two different antibodies, with variations in amino acid substitutions to enhance its efficacy. The patent also covers methods for producing the antibody, isolated nucleic acids encoding it, expression vectors, host cells, and pharmaceutical compositions containing the antibody.

Furthermore, the patent includes claims related to the use of the bispecific heterodimeric antibody for inhibiting vasodilation in patients with headache conditions, particularly migraines and cluster headaches. It also describes a method for treating migraine headaches by administering the antibody to patients in need. The antibody's constant region is derived from IgG immunoglobulins, and specific sequences for the light and heavy chains are provided, along with amino acid substitutions to introduce charged amino acids for improved functionality. Overall, the patent covers a comprehensive range of aspects related to the development, production, and therapeutic applications of the bispecific heterodimeric antibody.

To know more about GlobalData’s detailed insights on Amgen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies